These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25753637)

  • 1. Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus.
    Chan LC; Basuino L; Diep B; Hamilton S; Chatterjee SS; Chambers HF
    Antimicrob Agents Chemother; 2015 May; 59(5):2960-3. PubMed ID: 25753637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of an osteomyelitis case caused by dalbavancin, ceftaroline, and vancomycin non-susceptible methicillin-resistant Staphylococcus aureus.
    Dahdouh E; Díaz-Pollán B; Falces-Romero I; Mingorance J; Gómez-Gil R
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):2029-2032. PubMed ID: 33686556
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Gostev V; Sopova J; Kalinogorskaya O; Tsvetkova I; Lobzin Y; Klotchenko S; Sidorenko S
    Microb Drug Resist; 2019 Dec; 25(10):1401-1409. PubMed ID: 31329022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic analysis of Italian MRSA strains exhibiting low-level ceftaroline and ceftobiprole resistance.
    Bongiorno D; Mongelli G; Stefani S; Campanile F
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114852. PubMed ID: 31288948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients.
    Carnesecchi G; Lobello R; Liggieri L; Palmero C; Pescetto L; Morelli P; Castagnola E; Bandettini R
    J Chemother; 2018; 30(6-8):338-341. PubMed ID: 30375268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-Genome Sequencing of Methicillin-Resistant Staphylococcus aureus Resistant to Fifth-Generation Cephalosporins Reveals Potential Non-mecA Mechanisms of Resistance.
    Greninger AL; Chatterjee SS; Chan LC; Hamilton SM; Chambers HF; Chiu CY
    PLoS One; 2016; 11(2):e0149541. PubMed ID: 26890675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA.
    Schaumburg F; Peters G; Alabi A; Becker K; Idelevich EA
    J Antimicrob Chemother; 2016 Jan; 71(1):41-4. PubMed ID: 26443816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Rate of Ceftobiprole Resistance among Clinical Methicillin-Resistant
    Morroni G; Brenciani A; Brescini L; Fioriti S; Simoni S; Pocognoli A; Mingoia M; Giovanetti E; Barchiesi F; Giacometti A; Cirioni O
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.
    Abbott IJ; Jenney AW; Jeremiah CJ; Mirčeta M; Kandiah JP; Holt DC; Tong SY; Spelman DW
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7837-41. PubMed ID: 26392488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.
    Andrey DO; François P; Manzano C; Bonetti EJ; Harbarth S; Schrenzel J; Kelley WL; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):343-350. PubMed ID: 27744604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data.
    Horner C; Mushtaq S; Livermore DM;
    J Antimicrob Chemother; 2020 Nov; 75(11):3239-3243. PubMed ID: 32728710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus.
    Lee H; Yoon EJ; Kim D; Kim JW; Lee KJ; Kim HS; Kim YR; Shin JH; Shin JH; Shin KS; Kim YA; Uh Y; Jeong SH
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.
    Mendes RE; Tsakris A; Sader HS; Jones RN; Biek D; McGhee P; Appelbaum PC; Kosowska-Shick K
    J Antimicrob Chemother; 2012 Jun; 67(6):1321-4. PubMed ID: 22398650
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Gaikwad V; Gohel T; Panickar S; Chincholkar V; Mangalkar S
    Indian J Pathol Microbiol; 2016; 59(4):496-498. PubMed ID: 27721280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility testing of ceftobiprole against 880 European respiratory tract infection isolates of methicillin-resistant Staphylococcus aureus followed by whole genome sequencing of ceftobiprole-resistant isolates.
    Hawser S; Kothari N; Karlowsky JA; Wiktorowicz T; Hamed K
    Diagn Microbiol Infect Dis; 2020 Apr; 96(4):114978. PubMed ID: 31952866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.
    Fernandez R; Paz LI; Rosato RR; Rosato AE
    Antimicrob Agents Chemother; 2014 Oct; 58(10):5736-46. PubMed ID: 25022592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA.
    Varela MC; Roch M; Taglialegna A; Long SW; Saavedra MO; Rose WE; Davis JJ; Hoffman LR; Hernandez RE; Rosato RR; Rosato AE
    Commun Biol; 2020 Oct; 3(1):599. PubMed ID: 33093601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
    Werth BJ; Steed ME; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.
    Kelley WL; Jousselin A; Barras C; Lelong E; Renzoni A
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1922-30. PubMed ID: 25583724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.